Seattle, WA -- (SBWIRE) -- 09/27/2019 -- Global Injectable Drug Delivery Market, by Device Type (Prefilled Syringes, Autoinjectors, Pens, Conventional Syringes, Cartridges, Ampoules, Vials, and Others), by Material Type (Glass and Plastic), by Usability (Disposable and Reusable), by Route of Administration (Intravenous, Intramuscular, and Subcutaneous), by End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 15,939.0 million in 2017, and is projected to exhibit a CAGR of 8.3% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.
Key players in the market are focused on development of product and approval from regulatory authorities, in order to cater to the demands of patient diagnosed with chronic diseases. For instance, in October, 2018, Genentech announced the U.S. Food and Drug Administration (FDA) approval for single-dose prefilled syringes (PFS) for Xolair (omalizumab) as an additional formulation for both allergic asthma and chronic idiopathic urticaria (CIU) indications. Similarly, in August 2018, a new diabetes autoinjector pen by AstraZeneca- Bydureon Bcise was approved by European Commission, thereby offering additional treatment options for patients with type-2 diabetes.
Request Sample Copy of this Report - https://www.coherentmarketinsights.com/insight/request-sample/2768
Moreover, the market players are focused on increasing production capacity and facility launch to expand their offerings and services, which is expected to boost the market growth. For instance, in March 2019, Gerresheimer AG announced to build a new plant at North Macedonia, Europe to produce pharmaceutical plastic systems and prefillable syringes for the pharmaceutical industry and the medical technology sector.
Furthermore, increasing awareness regarding safety and concern for needlestick injuries is a major factor driving the global injectable drug delivery market. According to the Health Protection Agency (HPA) report in 2012, injuries among medical and dental professionals while treating patients increased by 131% (100-231) from 2002 to 2011.
Key players in the market are focused on adopting strategies such as collaborations and acquisitions to enhance their service offerings. For instance, in December 2016, SMC Ltd. acquired Oval Medical Technologies Ltd. to expand its drug delivery capabilities and product offerings to pharmaceutical manufacturers.
Similarly, in December 2017, Numedico Technologies signed an agreement with Mana Medical Services. According to agreement, the latter will distribute ClickZip Needle Retractable Safety Syringe in New Zealand and Australia.
Get PDF Brochure of Research Report - https://www.coherentmarketinsights.com/insight/request-pdf/2768
Key Takeaways of the Global Injectable Drug Delivery Market:
The global injectable drug delivery market is expected to exhibit a CAGR of 8.3% over the forecast period, owing to the product launch by the market players. For instance, in 2018, AbbVie GK and Eisai Co., Ltd. launched an autoinjection delivery system for HUMIRA for Subcutaneous Injection 40 mg Pen 0.4 mL and 80 mg Pen 0.8 mL.
Among material type, the plastic segment held a dominant position in the global injectable drug delivery market in 2018, owing to launch of plastic syringes and cartridges. For instance, in June 2016, Gerresheimer launched Gx RTF ClearJect, a prefillable plastic syringe with integrated cannula, which is made from high-performance cyclo olefin polymer (COP) plastic for sensitive medications and high-viscosity agents.
Among usability, the disposable segment held dominant position in the global injectable drug delivery market in 2018, owing to significant increase in self-administration to treat chronic diseases
Among route of administration, the subcutaneous segment held a dominant position in the global injectable drug delivery market in 2018, as pens and auto-injectors are mainly used for subcutaneous delivery of biopharmaceuticals, mainly for self-administrating
Among end user type, homecare settings segment held a dominant position in the globl injectable drug delivery market in 2018, owing to cost-effective and reliable home-based care for treating chronic conditions
Key players operating in the global injectable drug delivery market include, Becton, Dickinson and Company, Pfizer Inc., Novo Nordisk A/S, Gerresheimer AG, Carl-Zeiss-Stiftung, Terumo Corporation, Vetter Pharma-Fertigung GmbH & Co. KG, SHL Group, Owen Mumford Limited, Injex Pharma GmbH
To view the original version on The Express Wire visit https://www.coherentmarketinsights.com/market-insight/injectable-drug-delivery-market-2768
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.